Clinical Trial Detail

NCT ID NCT03973918
Title Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

malignant glioma

pleomorphic xanthoastrocytoma

Therapies

Binimetinib + Encorafenib

Age Groups: senior adult

Additional content available in CKB BOOST